Benefit of Bet v 1 contiguous overlapping peptide immunotherapy persists during first follow-up season

J Allergy Clin Immunol. 2018 Aug;142(2):678-680.e7. doi: 10.1016/j.jaci.2018.01.052. Epub 2018 Apr 17.
No abstract available

Publication types

  • Clinical Trial, Phase II
  • Letter
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Administration, Sublingual
  • Adult
  • Antigens, Plant / immunology
  • Antigens, Plant / therapeutic use*
  • Betula / immunology
  • Desensitization, Immunologic / methods*
  • Europe
  • Female
  • Follow-Up Studies
  • Humans
  • Hypersensitivity / immunology
  • Hypersensitivity / therapy*
  • Male
  • Middle Aged
  • Peptides / immunology
  • Peptides / therapeutic use*
  • Pollen / immunology*
  • Quality of Life

Substances

  • Antigens, Plant
  • Peptides
  • Bet v 1 allergen, Betula